Amended Statement of Ownership (sc 13g/a)
October 06 2016 - 3:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of
1934
(AMENDMENT NO. 1)*
OWC PHARMACEUTICAL RESEARCH CORP.
(Name of issuer)
Common Stock, $0.00001 par value per
share
(Title of class of securities)
67109N108
(CUSIP number)
October 3, 2016
(Date of Event Which Requires Filing of
this Statement)
Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:
* The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.
The information required in the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
Persons who respond to the collection of information contained
in this form are not required to respond unless the form displays a currently valid OMB control number.
SEC 1745 (1-06)
Page 1 of 5 pages
CUSIP No. 67109N108
|
13G
|
Page 2 of 5 Pages
|
1.
|
Name of Reporting Person
|
|
I.R.S. Identification Nos. of above persons (entities only).
|
|
|
|
VIS VIRES GROUP, INC.
|
|
EIN: 472303658
|
|
|
2.
|
Check the Appropriate Box if a Member of a Group (See Instructions)
|
|
|
|
(a)
¨
|
|
(b)
¨
|
|
|
3.
|
SEC Use Only
|
|
|
|
|
4.
|
Citizenship or Place of Organization
|
Delaware
|
Number of
|
5.
|
Sole Voting Power
|
Shares
|
|
0
|
Beneficially
|
|
|
Owned by
|
6.
|
Shared Voting Power
|
Each
|
|
|
Reporting
|
|
|
Person
|
7.
|
Sole Dispositive Power
|
With:
|
|
0
|
|
|
|
|
8.
|
Shared Dispositive Power
|
|
|
|
9.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
|
|
|
|
0
|
|
|
10.
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
|
|
|
|
|
11.
|
Percent of Class Represented by Amount in Row (9)
|
|
0.00%
|
|
|
12.
|
Type of Reporting Person (See Instructions)
|
|
|
|
CO
|
CUSIP No. 67109N108
|
13G
|
Page 3 of 5 Pages
|
|
Item 1
|
(a)
|
Name of Issuer:
|
|
|
|
OWC PHARMACEUTICAL RESEARCH CORP., a Delaware corporation
|
|
|
|
|
|
|
(b)
|
Address Of Issuer's Principal Executive Offices:
|
|
|
|
22 Shacham Street,
P.O. Box 8324
Petach Tikva, 4918103
Israel
|
|
|
|
|
|
Item 2
|
(a)
|
Name of Person Filing:
|
|
|
|
VIS VIRES GROUP, INC.
|
|
|
|
|
|
|
(b)
|
Address of Principal Business Office, or, if none, Residence:
|
|
|
|
111 Great Neck Road, Suite 216, Great Neck, NY 11021
|
|
|
|
|
|
|
(c)
|
Citizenship:
|
|
|
|
New York
|
|
|
|
|
|
|
(d)
|
Title of Class of Securities:
|
|
|
|
Common Stock, $0.00001 par value per share
|
|
|
|
|
|
|
(e)
|
Cusip Number:
|
|
|
|
67109N108
|
|
|
|
|
|
Item 3
|
If this statement is filed pursuant to §240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
|
|
|
|
|
|
|
(a)
|
¨
Broker or dealer
registered under section 15 of the Act (15 U.S.C. 78o).
|
|
|
(b)
|
¨
Bank as defined in
section 3(a)(6) of the Act (15 U.S.C. 78c).
|
|
|
(c)
|
¨
Insurance company as
defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
|
|
|
(d)
|
¨
Investment company
registered under section 8 of the Investment Company Act (15 U.S.C. 80a-8).
|
|
|
(e)
|
¨
An investment adviser
in accordance with §240.13d-1(b)(1)(ii)(E).
|
|
|
(f)
|
¨
An employee benefit
plan or endowment fund in accordance with §240.13d-1(b)(ii)(F).
|
|
|
(g)
|
¨
A parent holding
company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
|
|
|
(h)
|
¨
A savings association
as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
|
|
|
(i)
|
¨
A church plan that is
excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C.
80a-3);
|
|
|
(j)
|
¨
Group in accordance
with §240.13d-1(b)(ii)(J).
|
CUSIP No. 67109N108
|
13G
|
Page 4 of 5 Pages
|
|
|
(a) Amount beneficially owned 0
|
|
|
(b) Percent of class: 0.00%
|
|
|
(c) Number of shares as to which the person has:
|
|
|
(i) Sole power to vote or to direct the vote 0
|
|
|
(ii) Shared power to vote or to direct the vote
|
|
|
(iii) Sole power to dispose or to direct the disposition of 0
|
|
|
(iv) Shared power to dispose or to direct the disposition of
|
|
Item 5
|
Ownership of Five Percent or Less of a Class
|
If this statement is being filed to report the fact that as of the date hereof the reporting person has
ceased to be the beneficial owner of more than five percent of the class of securities, check the following
x
.
|
Item 6
|
Ownership of More Than Five Percent on Behalf Of Another
Person
|
|
Item 7
|
Identification and Classification of the Subsidiary
Which Acquired the Security Being Reported on By the Parent Holding Company
|
|
Item 8
|
Identification and Classification of Members of The
Group
|
|
Item 9
|
Notice of Dissolution of Group
|
|
(a)
|
The following certification shall be included if the statement
is filed pursuant to §240.13d-1(b):
|
By signing below I certify that, to the best of my
knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not
acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities
and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
|
(b)
|
The following certification shall be included if the statement
is filed pursuant to §240.13d-1(c):
|
By signing below I certify that, to the best of my
knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect
of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with
or as a participant in any transaction having that purpose or effect.
CUSIP No. 67109N108
|
13G
|
Page 5 of 5 Pages
|
SIGNATURE
After reasonable inquiry and to the best
of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
October 6, 2016
|
|
Date
|
|
|
|
/s/Curt Kramer
|
|
Signature
|
|
|
|
Curt Kramer, President
|
|
Name/Title
|
The original statement shall be signed
by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf
of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence
of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however,
that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name
and any title of each person who signs the statement shall be typed or printed beneath his signature.
NOTE
: Schedules filed in paper format shall include a
signed original and five copies of the schedule, including all exhibits.
See
§240.13d-7 for other parties for whom
copies are to be sent.
Attention: Intentional misstatements
or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Mar 2024 to Apr 2024
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Apr 2023 to Apr 2024